C

CytoTools AG
XETRA:T5O

Watchlist Manager
CytoTools AG
XETRA:T5O
Watchlist
Price: 101.26 EUR 0.98%
Market Cap: 52.8m EUR
Have any thoughts about
CytoTools AG?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-77.6
Current
-63.4
Median
4.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-77.6
=
Enterprise Value
51.7m EUR
/
EBITDA
-666.5k EUR
All Countries
Close
EBITDA Growth
DE
C
CytoTools AG
XETRA:T5O
Average EV/EBITDA: 49.6
Negative Multiple: -77.6
N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
19.5
64%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.1
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.4
53%
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
9%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.4 N/A
AU
CSL Ltd
ASX:CSL
22.5
42%
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
230.5
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -35.3 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More